# Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology

> **NCT01020838** · PHASE3 · COMPLETED · sponsor: **Life Molecular Imaging SA** · enrollment: 218 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Florbetaben (BAY94-9172)

## Key facts

- **NCT ID:** NCT01020838
- **Lead sponsor:** Life Molecular Imaging SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2011-09
- **Final completion:** 2013-12
- **Target enrollment:** 218 (ACTUAL)
- **Last updated:** 2016-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01020838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01020838, "Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01020838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*